These compounds also act against cervical cancer through Sub-G1 phase cell cycle arrest triggering DNA damage, inhibit the growth of transplantable sarcoma 180, increase the number of white blood cells (WBC), CD4+ T-, the CD4+/CD8+ ratio, IL-12, and TLR-4, decrease IL-10 and HeLa cell proliferation, reduce the production of cytokine/chemokine and the expression levels of CD80, CD86, CD83, Bax, and downregulate the Bcl-2 level in a concentration-dependent manner. Here, CD4 is linked to cervical cancer.